

November 4, 2023

BrightPath to Update the Preclinical Data of HER2-CAR-T at SITC 2023

Tokyo, Japan - November 4, 2023/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that Company will present preclinical data on HER2-CAR-T cells at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2023, November 1-5, San Diego). Summary of the abstracts and the electronic posters will be posted on the website of BrightPath after SITC 2023 is held.

Abstract number 303

- PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma

Date & Time: 9 a.m.-9 p.m. EST on Saturday, November 4, 2023

BrightPath has developed a novel autologous HER2-targeting CAR-T cells known as BP2301, utilizing a non-viral PiggyBac transposon system that endows the CAR-T cells with an abundance of stem cell memory-like T cells (Tscm). A Phase 1 clinical trial is currently underway to evaluate the safety and preliminary efficacy of BP2301 in patients with HER2-expressing sarcoma and gynecologic malignancies.

We previously reported BP2301 effectively eradicated the tumors and this anti-tumor activity remained sustained in sarcoma and gynecological cancer xenograft models. In the present study, we have demonstrated the anti-tumor efficacy of BP2301 in a cholangiocarcinoma xenograft model using patient-derived tumor cells with low HER2 expression and resistance to trastuzumab and T-DM1, and its durability was found to be consistent with their PK profiles.

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.

For more information, visit www.brightpathbio.com

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com